Passar para o conteúdo principal


Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting

Whitepapers

Tech Sheet on Midostaurin API

Tech Sheet on Midostaurin API

Midostaurin is a small molecule that inhibits multiple receptor tyrosine kinases. In vitro biochemical or cellular assays have shown that Midostaurin or its major human active metabolites CGP62221 and CGP52421 inhibit the activity of wild type FLT3, FLT3 mutant kinases (ITD and TKD), KIT (wild type and D816V mutant), PDGFRα/β, as well as members of the serine/threonine kinase PKC (protein kinase C) family.

Midostaurin has global sales of 188 million USD with a 74% year-over-year (YoY) growth and 58 Kg growth at 67% YoY. It is expected to become around 200 Kg market by 2025. The global Midostaurin market is projected to grow at a CAGR of 4.6% between 2022 and 2030.

The growth is primarily driven by Europe, China, and the rest of the world (ROW) markets. In addition, more approvals for novel therapies and ongoing trials for all form of Acute myeloid leukemia (AML) would further propel the market during the forecast period (2021-2030).

Dr. Reddy's API Offering

  • Crystalline form II (same as innovator form) and amorphous form.
  • Dr. Reddy's is among the earliest generic API manufacturers globally to file the US DMF for Midostaurin API for both polymorph forms.
  • Quality by design (QbD) based API development for a consistent quality profile.

To know more about our API offerings, please read the Tech sheet on Midostaurin API by filling the contact form below.

Explore other Whitepapers:

Know More

Download Now

Preencha o formulário de contato abaixo para visualizar o white paper

Aviso Legal

Nenhuma informação neste site, incluindo qualquer referência a qualquer produto ou serviço, constitui uma oferta de venda ou pode ser interpretada como representando uma oferta de venda. Produtos protegidos por patentes válidas não são oferecidos ou fornecidos para uso comercial. No entanto, em certos casos, a critério exclusivo do Dr. Reddy e sujeito a requisitos legais locais, as quantidades de pesquisa de tais produtos podem ser oferecidas para fins de submissões regulatórias sob a Seção 107A da Lei de Patentes da Índia (isenção Bolar), onde quer que tais isenções regulatórias existam. Os compradores devem fazer sua avaliação independente do produto ou serviço, incluindo o cenário de patentes em seus respectivos mercados e serão responsáveis ​​por todas as responsabilidades relacionadas a patentes. O Dr. Reddy se isenta de todas as garantias, expressas ou implícitas, incluindo, entre outras, garantias de comercialização, adequação a uma finalidade específica e não violação.

Empresa

Contate-Nos

Follow Us on

  • Twitter

Dr. Reddy’s Laboratories, 8-2-337,
Banjara Hills Rd Number 3,
SBI Executive Enclave, Green Valley,
Banjara Hills, Hyderabad,
Telangana 500034
Phone: 040 4900 2222

© 2025 Dr. Reddy’s Laboratories Ltd. All rights reserved.

Dr. Reddy’s Laboratories, 8-2-337,
Banjara Hills Rd Number 3,
SBI Executive Enclave, Green Valley,
Banjara Hills, Hyderabad,
Telangana 500034
Phone: 040 4900 2222

  • Twitter

© 2025 Dr. Reddy’s Laboratories Ltd.
All rights reserved.

X

Let’s talk API sourcing live at

Tackle sourcing bottlenecks and compliance hurdles

Hall E1 Booth H28 24-26 June 2025, Shanghai

Book a Meeting